iris/neoplasms

TECHNICAL FIELD The present disclosure relates to peptides for treating cancer, to compositions comprising such peptides, and to methods of using the peptides. BACKGROUND Cancer continues to be a leading cause of death with over 1.6 million new cases of cancer being diagnosed in 2012 and over

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

SEQUENCE LISTING The present application is being filed along with a sequence listing in electronic format. The sequence listing is provided as a file entitled, "VLX0001-201-US 20131212 SequenceListing_ST25", created on Dec. 11, 2013 which is 90 Kb in size. The information in the electronic format

The present invention relates to antibodies that bind CD47 and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor. CD47 is a cell surface receptor comprised of an extracellular IgV set domain, a 5 membrane spanning

INCORPORATION OF SEQUENCE LISTING The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled, "VLX0001-201CIP2 US_SequenceListing", created on Jun. 11, 2015, which is 168,755 bytes in size. The information in the

BACKGROUND The present disclosure relates to antibodies that bind CD47, including that of humans and other mammalian species, and their use in treating conditions and disorders, such as ischemia-reperfusion injury (IRI) and cancers, mediated by this receptor. CD47 is a cell surface receptor

BACKGROUND OF THE INVENTION The invention relates to a method and device having a collimator for limiting a beam of high-energy radiation directed from an essentially point-shaped radiation source onto an object to be treated for stereotactic, conformal radiation therapy of tumors, wherein the